Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30971332 | 0.76 | P2RX7 (0.32) | CYP2C19CYP4F2CYP4A11MAPK1 | |
| SCHEMBL19253411 | 0.74 | CYP4F2 (0.33) | CYP2C19CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL1534508 | 0.74 | CD274 (0.35) | CYP2C19CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL22658828 | 0.74 | LMNA (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL21812834 | 0.73 | CYP4F2 (0.39) | CYP2C19CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL25416797 | 0.72 | GAA (0.38) | CYP2C19CYP4F2CYP4A11MEN1ALDH1A1 | |
| SCHEMBL26686303 | 0.71 | ALDH1A1 (0.41) | CYP2C19YTHDC1CYP4F2CYP4A11TP53 | |
| SCHEMBL25219875 | 0.71 | CYP2C19 (0.39) | CYP2C19YTHDC1CYP4F2CYP4A11TP53 | |
| SCHEMBL28813578 | 0.71 | YTHDC1 (0.41) | CYP2C19YTHDC1CYP4F2CYP4A11TP53 | |
| SCHEMBL1485133 | 0.71 | CYP2C19 (0.38) | CYP2C19YTHDC1CYP4F2CYP4A11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-07-03 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| CN-114981251-A | Diphenyl furan derivative cathepsin K inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021147882-A1 | DIBENZOFURAN DERIVATIVE CATHEPSIN K INHIBITOR, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | CYP2C19 564/4885YTHDC1 4673/4885CYP4F2 363/4885 |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | CYP2C19 564/4885YTHDC1 4673/4885CYP4F2 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.